# Wolverine Stack: BPC-157 and TB-500 Preclinical Research Digest > The Wolverine stack pairs BPC-157 and TB-500 — two peptides studied across tendon, muscle, bone, and vascular models. Plain-language summaries of the published preclinical record. ## What Is the Wolverine Stack? The Wolverine stack is a combined preparation of BPC-157 (Body Protection Compound-157) and TB-500 (a synthetic fragment of thymosin beta-4), two structurally unrelated peptides that have each accumulated independent preclinical evidence in tissue-repair models. BPC-157 is a synthetic pentadecapeptide — fifteen amino acids in the sequence GEPPPGKPADDAGLV — derived from a protein isolated from human gastric juice. Its molecular weight is 1,419.5 Da. TB-500 corresponds to the LKKTET actin-binding motif region of thymosin beta-4 (Tβ4), a naturally occurring 43-amino acid polypeptide found at high concentrations in platelets, macrophages, and wound fluid. The two compounds operate through complementary mechanisms at different stages of the tissue-repair cascade. BPC-157 drives angiogenesis and matrix remodeling primarily through VEGFR2 upregulation and nitric oxide signaling. TB-500 promotes endothelial and myoblast cell migration by sequestering G-actin via the LKKTET motif and suppresses inflammatory signaling through NF-kB inhibition [13][14]. The informal name references the accelerated tissue regeneration of a fictional character — the editorial framing captures the studied scope of activity across multiple tissue types, not a clinical claim. The combination emerged in biohacking and performance-recovery communities as a convention; it has not been tested as a co-formulation in a controlled peer-reviewed animal or human trial. ## What the Preclinical Literature Has Measured Across the BPC-157 record, the most consistent finding is accelerated tendon and ligament repair. In rats with surgically detached Achilles tendons, BPC-157 at 10 µg/kg, 10 ng/kg, and 10 pg/kg (intraperitoneal) improved functional Achilles index values, load-to-failure biomechanics, stiffness, and Young elasticity modulus compared with untreated controls [1]. In a medial collateral ligament transection model, consistent functional, biomechanical, macroscopic, and histological improvements were observed at 90 days across intraperitoneal, topical, and oral routes [2]. Myotendinous junction disruption has also been studied. BPC-157 at 10 µg/kg and 10 ng/kg restored myotendinous junction function, with prominent fibroblast proliferation producing reticulin and collagen fibers [6]. A 2025 study found that per-oral BPC-157 recovered muscle-to-bone continuity at 3 months after complete surgical quadriceps detachment [7]. For TB-500 (thymosin beta-4), the primary documented mechanism is G-actin sequestration — the LKKTET hexapeptide motif binds globular actin in a 1:1 complex, reducing intracellular actin concentration and promoting cell motility. In vitro, thymosin beta-4 stimulated directed migration of human umbilical vein endothelial cells four- to sixfold over media controls [13]. Thymosin beta-4 has also reached Phase 2 clinical investigation: topical formulations were evaluated in patients with venous stasis ulcers and pressure ulcers and found to be safe and well tolerated [22]. ## The Wolverine Peptide Blend The wolverine peptide blend refers to a pre-combined lyophilized preparation containing both BPC-157 and TB-500, offered by research-supply vendors as a single reconstituted product. The blend convention has no peer-reviewed optimization basis. The 1:1 mass ratio most commonly described in community discussions is not derived from a published dose-optimization study [18]. All quantitative evidence for either component comes from studies examining each peptide independently. ## Injury Models Studied in Preclinical Research The BPC-157 preclinical record spans a notably broad range of injury types: tendon-to-bone avulsion [1], ligament transection [2], myotendinous junction disruption [6], muscle-to-bone reattachment [7], segmental bone defects in rabbits [8], gastric ulcer protection (45.7–65.6% inhibition ratio at 800 ng/kg intramuscular) [11], spinal cord compression injury [9], and wound/burn healing [20]. For TB-500, injury models include skeletal muscle regeneration in dystrophin-deficient mice — 150 µg twice weekly for 6 months [16] — and wound healing models showing 42% increase in reepithelialization over saline controls [22]. ## BPC-157 and TB-500: Two Distinct Compounds BPC-157 is a synthetic pentadecapeptide derived from a gastric protein sequence with primary mechanisms involving VEGFR2-driven angiogenesis and the Src-Caveolin-1-eNOS nitric oxide pathway. TB-500 is a synthetic fragment of thymosin beta-4 with primary mechanisms involving G-actin sequestration via the LKKTET motif and NF-kB anti-inflammatory signaling. The two compounds are structurally unrelated and mechanistically distinct. They do not operate through the same pathway, target the same receptor, or share a molecular scaffold. ## References [1] Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157. J Orthop Res. 2006;24(5):982-989. https://pubmed.ncbi.nlm.nih.gov/16583442/ [2] Cerovecki T, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-1161. https://pubmed.ncbi.nlm.nih.gov/20225319/ [6] Japjec M, et al. Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats. Biomedicines. 2021;9(11):1547. https://pmc.ncbi.nlm.nih.gov/articles/PMC8615275/ [7] Matek D, et al. BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle. Pharmaceutics. 2025;17(1):119. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11768438/ [8] Sebecic B, et al. Osteogenic effect of BPC-157 on segmental bone defect in rabbits. Bone. 1999;24(3):195-202. https://pubmed.ncbi.nlm.nih.gov/10071911/ [9] Perovic D, et al. Novel Therapeutic Effects in Rat Spinal Cord Injuries. Curr Issues Mol Biol. 2022;44(5):1960-1975. https://pmc.ncbi.nlm.nih.gov/articles/PMC9164058/ [11] Xue XC, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10(7):1032-1036. https://pubmed.ncbi.nlm.nih.gov/15052688/ [13] Philp D, Goldstein AL, Kleinman HK. Thymosin beta 4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113-115. https://pubmed.ncbi.nlm.nih.gov/15037013/ [14] Qiu P, et al. Thymosin beta4 inhibits TNF-alpha-induced NF-kB activation, IL-8 expression. FASEB J. 2011;25(6):1815-1826. https://pmc.ncbi.nlm.nih.gov/articles/PMC3101037/ [16] Spurney CF, et al. Evaluation of Skeletal and Cardiac Muscle Function after Chronic Administration of Thymosin beta-4. PLoS One. 2010;5(2):e8976. https://pmc.ncbi.nlm.nih.gov/articles/PMC2813286/ [18] Yuan C, et al. From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair. Int J Mol Sci. 2026;27(6):2876. https://pubmed.ncbi.nlm.nih.gov/41898733/ [20] Seiwerth S, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021;12:627533. https://pmc.ncbi.nlm.nih.gov/articles/PMC8275860/ [22] Philp D, Goldstein AL, Kleinman HK. Thymosin beta 4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113-115. https://pubmed.ncbi.nlm.nih.gov/15037013/ --- A hard-block reading of the BPC-157 and TB-500 preclinical record — two compounds, one literature digest, no clinic and no vendor behind the byline.